Jean-marc Grognet

Biography

 Jean-Marc Grognet became the chief executive of Genopole on 1 February 2017. Formerly, he headed the Institute of Biomedical Imaging (I2BM), and furthermore directed "Technologies for Health", a transversal program of the French Alternative Energies and Atomic Energy Commission (CEA). Now 60 years old, Mr. Grognet is a graduate of the Paris-Descartes University’s school of pharmacy (1980) and the Sorbonne Graduate Business School (1984). He also holds a PhD in molecular pharmacology and an HDR (accreditation to supervise research), both obtained from Paris-Descartes University in 1984 and 1998 respectively. Mr. Grognet worked at the CEA for most of his career. From 1985 to 2000, he led the Laboratory of Drug Metabolism Research and the Clinical Pharmacology Group within the CEA’s health and life sciences division. Thereafter, he joined the CEA’s technological research division, for which he was the scientific and research director between 2002 and 2007 as a specialist in biotechnologies. In 2008, he joined the General Directorate for Competitiveness, Industry and Services of the French Ministry for the Economy, Finance and Industry as the assistant director for the "industries for health, chemistry and new materials" sector.  In 2011, Mr. Grognet returned to the CEA to head the Institute of Biology and Technology Saclay within the Health and Life Sciences Division. He then became the director of valorization in 2014 before being named as head of I2BM in 2016.  Mr. Grognet has authored more than a hundred publications and communications, thus earning a seat in the French National Academy of Pharmacy. In 1991, with his particular expertise in nano and biotechnologies, Mr. Grognet participated in the creation of the start-up SPI Bio, now a part of Bertin Pharma. He has been the president of the Interministerial Group for Chemical Products since 2012 and a member of the Educational Council of the National Institute for Nuclear Sciences and Techniques since 2013.

Research Interest

 Jean-Marc Grognet became the chief executive of Genopole on 1 February 2017. Formerly, he headed the Institute of Biomedical Imaging (I2BM), and furthermore directed "Technologies for Health", a transversal program of the French Alternative Energies and Atomic Energy Commission (CEA). Now 60 years old, Mr. Grognet is a graduate of the Paris-Descartes University’s school of pharmacy (1980) and the Sorbonne Graduate Business School (1984). He also holds a PhD in molecular pharmacology and an HDR (accreditation to supervise research), both obtained from Paris-Descartes University in 1984 and 1998 respectively. Mr. Grognet worked at the CEA for most of his career. From 1985 to 2000, he led the Laboratory of Drug Metabolism Research and the Clinical Pharmacology Group within the CEA’s health and life sciences division. Thereafter, he joined the CEA’s technological research division, for which he was the scientific and research director between 2002 and 2007 as a specialist in biotechnologies. In 2008, he joined the General Directorate for Competitiveness, Industry and Services of the French Ministry for the Economy, Finance and Industry as the assistant director for the "industries for health, chemistry and new materials" sector.  In 2011, Mr. Grognet returned to the CEA to head the Institute of Biology and Technology Saclay within the Health and Life Sciences Division. He then became the director of valorization in 2014 before being named as head of I2BM in 2016.  Mr. Grognet has authored more than a hundred publications and communications, thus earning a seat in the French National Academy of Pharmacy. In 1991, with his particular expertise in nano and biotechnologies, Mr. Grognet participated in the creation of the start-up SPI Bio, now a part of Bertin Pharma. He has been the president of the Interministerial Group for Chemical Products since 2012 and a member of the Educational Council of the National Institute for Nuclear Sciences and Techniques since 2013.